Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996018405 - PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION

Publication Number WO/1996/018405
Publication Date 20.06.1996
International Application No. PCT/US1995/014982
International Filing Date 05.12.1995
Chapter 2 Demand Filed 30.05.1996
IPC
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/198 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 275/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
275Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
04having nitrogen atoms of urea groups bound to acyclic carbon atoms
06of an acyclic and saturated carbon skeleton
16being further substituted by carboxyl groups
CPC
A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61K 31/704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 275/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
275Derivatives of urea, i.e. compounds containing any of the groups , the nitrogen atoms not being part of nitro or nitroso groups
04having nitrogen atoms of urea groups bound to acyclic carbon atoms
06of an acyclic and saturated carbon skeleton
16being further substituted by carboxyl groups
Y10S 514/93
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
93Vasoconstrictor, nondecongestant
Applicants
  • THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. [US]/[US] (AllExceptUS)
  • GROSS, Stevens, S. [--]/[US] (UsOnly)
  • GRIFFITH, Owen, W. [--]/[US] (UsOnly)
Inventors
  • GROSS, Stevens, S.
  • GRIFFITH, Owen, W.
Agents
  • SPECTOR, Eric, S.
Priority Data
08/354,58512.12.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION
(FR) PREVENTION DE LA TRANSFORMATION DE LA CITRULLINE EN ARGININOSUCCINATE AFIN DE LIMITER LA SURPRODUCTION D'OXYDE NITRIQUE PATHOLOGIQUE
Abstract
(EN)
Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of $g(a)1-adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate sythetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine-induced hypotension.
(FR)
L'administration d'agents réduisant l'activité de l'argininosuccinate synthétase, tels que des agents bloquant l'induction de l'argininosuccinate synthétase (p.ex., des antibiotiques qui se fixent aux séquences d'ADN présentes dans la région régulatrice amont du gène de l'argininosuccinate synthétase, tels que la mithramycine) et des inhibiteurs de l'argininosuccinate synthétase (p.ex., des antagonistes de L-citrulline tels que la méthylcitrulline et des antagonistes de L-aspartate tels que le D-aspartate) permet de prévenir ou traiter la septicémie ou l'hypotension générale induite par la cytokine, permet, lors du traitement de la septicémie ou de l'hypotension générale induite par la cytokine, de rétablir la sensibilité vasculaire aux effets des agonistes $g(a)1-adrénergiques, et permet de supprimer une réaction immunitaire, p.ex., lors du traitement des inflammations. Selon un mode de réalisation, on utilise certains agents réduisant l'activité de l'argininosuccinate synthétase avec des antagonistes d'arginine pour traiter la septicémie ou l'hypotension induite par la cytokine.
Also published as
Latest bibliographic data on file with the International Bureau